Kathy Tracey, LPN, CCRC, Manager of Clinical Research, Chevy Chase Clinical Research, Chevy Chase, MD; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc., Roseville, MN
First multi-center study of a next-generation fecal microbiota transplant (FMT) product.
- Phase 2 open-label study of RBX2660 (microbiota suspension) for recurrent C. diff. infection
- Multicenter, prospective, study using a single protocol under an FDA Investigational New Drug application
- Objective: Evaluate the safety and effectiveness of RBX2660